our product revenue call well NERLYNX total licensees. today. second all consists XXXX Total of for which for as Mariann net, the of thank and joining quarter from includes revenue reported revenue Today, as royalties million. our sub you, Thank you sales, entirely Puma $XX.X of
XXXX, Product in as in revenue in $XX.X $XX.X million increases quarter from expected QX of net $XX.X QX reported represents XXXX. million XXXX the which second million and was reported
Product $X.X revenue for XXXX. drawdown of inventory was XXXX pharmacies million $X.X at and the QXX of of quarter XXXX $X the specialty in our million specialty second revenue in Royalty by impacted compared quarter distributors. $X to QX XXXX million million second in was approximately
of sold XXXX reported bottles XXX XXXX, of We bottles second in of from of in sold QX XXXX. NERLYNX quarter X,XXX an the increase
QX last inventory QX on in call, XX estimate XXXX. in XXXX, increased by XXXX we we about about XXX of declined XXX noted quarter's I bottles. bottles and further QX by In bottles inventory that estimate about was subsequently by then As that reduced
slides. In Jeff prescriptions new QX compared his further comments were QX will down up total to XXXX provide details were and QX approximately approximately of compared XXXX, prescriptions to NRx X.X% XXXX. and in or XX.X%
on of clinical the for additional of our components activities, a Then, key highlights follow review provide of now statements quarter. Ludwig second will of add will with NERLYNX I color the the financial Jeff will quarter Nougues Maximon commercial XXXX.
head cancer. including of In In and single-agent anticancer cancer clinical the we the drugs in investor shown combination of treatment alisertib lung types other cancer, triple-negative cancer breast activity to-date, had XXXX, receptor-positive and drug cell our different cancer, in in-licensed has breast call in we many that activity alisertib neck announced cancer, hormone and October with trials Takeda. small from
is extensive. activity treated company-sponsored clinical a And previous large with and in clinical this, clinical development T-cell XX lymphoma. Takeda's non-Hodgkin has shown clinical was plan database are there trials. who with peripheral also over patients trials X,XXX previous well-characterized drug alisertib across The in due safety lymphoma to
small prior cell as was Phase the Lancet this was previously previously In experience shown cohorts as X is of was in tested terms in tumors. with lung trial In published single alisertib solid on cancer, that tested in a in agent several is trial, of Oncology. patients the -- alisertib a slide,
the In up of lung Patients cell previously metastatic cell the to a administered to alisertib monotherapy were lung regimens study for design at administration break. two days had XX-day a dose monotherapy with of followed by the small prior cancer who seven milligrams received small involved the cohorts, cancer cytotoxic alisertib patients in XX BID setting.
table see duration you chemotherapy a of of sensitive in months. X.X the with a alisertib of resulted disease, right on slide, rate of the and response XX% As in the can in patients response
For small with chemotherapy-resistant results resulted with drugs chemotherapy chemotherapy-resistant response approved cancer. in the We a to recently rate compare in duration of refractory response note in and the patients alisertib cell XX% disease, months. that disease patients with of or chemotherapy-resistant favorably of lung X.X a results
can resistant see see slide, plot bars light on the cancer the the patients bars the the represent blue cell with alisertib in patients for small the this you As represent treated waterfall relapsed and slide, you chemotherapy-sensitive trial lung refractory chemotherapy patients. the with red treated can the or monotherapy. On
the expect events alisertib one and that would see leukopenia the On the are the The neutropenia, or drug trial three cycle. this main in for trial. a can similar higher for slide, targets thrombocytopenia. grade cell to in were AEs The anemia, you what AEs adverse
This cell a the in XXXX. second-line tested of Phase lung was patients Thoracic randomized, paclitaxel trial cancer. Alisertib double-blind plus X of Oncology plus published in paclitaxel Journal in alisertib was versus with placebo-controlled in trial also small placebo
and the paclitaxel per was days XX with a and on milligrams days monotherapy administered trial for XX weeks to being dosed to eight to XX XX at XX different meter on at squared eight alisertib than at Alisertib plus dose dosed in BID milligrams three, one, three XX. IV one
than and with cycles. XX-day stratified at treatment primary Randomization the paclitaxel after dosed relapsed days but defined XXX and days relapsed IV to paclitaxel with greater equal for XX after defined after XX definition placebo as refractory XX than milligrams sensitive one, or treatment XX%, in common squared plus was of or treatment. primary meter less received relapse by primary on resistant comparator on per than The each as eight based type less type, on days
the relapses administration approximately initial response. written The of clinical and NCCN record after than last protocol relapse so which therapy in the relapse treatment definition with sponsor practice rather type was from line guidelines initial from as through recorded primary trial, to the were time initially amendment that by is chemotherapy, response. which the was mid-way protocol corrected the of A from platinum-based treatment stratification type done
of and relapse To PFS of maintain primary stratification original balance the the using analyzed type. endpoint was definition
which analysis, stratification the sensitivity definition However, also was performed. used corrected
in The analysis also extensive and alterations of biomarker genetic measured outcome. immunohistochemistry incorporated with analysis by c-Myc expression a trial with retrospective an clinical prespecified a analysis ctDNA of
shown was treat primary or using of p-value p-value As original hazard X.XX the corrected the survival, of intent population endpoint the with a the X.XX definition, PFS, with was the using hazard a was the is on of trial ratio to slide, for in ratio X.XXX, the progression-free the X.XXX. definition
or with of refractory resistant a patients the X.XXX. was relapse, p-value the with For hazard chemotherapy ratio X.XX,
with the OS X.XXX. of and ratio a population, corrected was a the X.XX p-value hazard ITT hazard a of showed the the definition, with ratio X.XX For of using p-value X.XXX
an prospective analysis extensive in there testing mentioned, c-Myc. As previously biomarker for the was done trial with
for IHC patients paclitaxel the within for trial months who median plus X.XX found the c-Myc hazard be was were arm a ratio PFS the trial plus For the expression, PFS median X.XX the in to arm positive the X.XX alisertib paclitaxel of of months. placebo for in and
including and note, RBX and found frequent of RBX. trial while mutations CDKX, mutation incorporated alterations with approximately of mutations, and low patients CDKX, RBLX The RBLX, having were also the with Of very RBLX the were mutations an patients RBLX frequency. with XX% cycle cell RBX the analysis genes, most
placebo survival shown The As for subgroup alisertib of placebo in X.XXX for patients the of X.X the X.XXX. the months, months, X.XXXXX. the plus arm ratio and the was p-value was and cycle p-value with hazard hazard a the arm with arm for arm patients was a on the ratio the X.XX in X.XX while of paclitaxel months overall months a and alisertib plus X.XXX with was paclitaxel PFS mutations, cell slide, X.X
Slide seen in There neutropenic for febrile were higher the the and should alisertib trial profile four the be AE the also septic trial in were the X grade alisertib eight sepsis, trial, for to monotherapy. anemia AEs of shock. shows or higher and on drug-related expected neutropenia, prior rates count, arm of which neutropenia due Phase X fatalities based neutrophil decreased
an lung alisertib accelerated cancer FDA small Puma discuss to recently cell plan small the possibility pathway exploring cancer. met of intent the alisertib the in for the of lung with cell in for clinical approval with development
biomarker-focused X Phase the combination versus plus of and trial paclitaxel OS plus that plus The paclitaxel PFS alisertib paclitaxel placebo placebo. in to alisertib subgroups, randomized a plus demonstrated compared previous paclitaxel advantage of demonstrated
biomarker lung these the in similar unknown. cell alisertib biomarker cancer. with Hence, of not the previous is analyses in However, patients small performed monotherapy trial were monotherapy in efficacy subgroups
first-line of quarter, FDA in lung XX with small third on the ALI-XXXX, enroll X cell stage patients is platinum-based and is name trial patients alisertib the will cell small cancer. shown In with up slide who filed Puma for chemotherapy The lung after Puma progressed nine. monotherapy study with a which The Phase cancer its trial IND to immunotherapy. extensive
biomarkers to the determines proceed, tissue-based must BID Patients of an of is be alisertib evaluation as seek cycle. at X can the be and to in this every trial initiate XX XXXX. Puma well X half study Puma dosed as second biomarkers XX-day an plans Once on safe of milligrams the that analysis the for perform evaluation the the to days efficacy. biopsies provide interim FDA and will analyzed will through
response, will control, shown slide of endpoint points secondary rate, response is be end primary As the survival and trial survival. duration of overall objective the on progression-free disease of with XX,
to be also any will there selected well looking efficacy better prespecified company whether in endpoints each as subgroups within seen of assess is subgroup. as The at biomarker biomarker these
accelerated subgroups in Thoracic a approval correlate previously biomarker is goal would that in trial If the potential seen the Oncology. The paclitaxel these the represent of alisertib randomized alignment it strategy. there biomarker in the Journal to efficacy believes the be was the two, from the between of company published to could subgroups plus efficacy
is randomized here efficacy will goal in biomarker to ALI-XXXX execution alisertib that parallel As be the Again, XX, the slide the the subgroups be seen of of the will look sorry, correlate paclitaxel the I'm plus alisertib to the Puma subgroups efficacy in and trial at trial. monotherapy performing biomarker biomarker analysis same and trial. the -- its in clinical in patients seen with in of
explore to the the As for approval is the FDA meeting cell shown small cancer. on an slide, company accelerated it potential in anticipates alisertib analysis lung with performed has for the once pathway this
We there months. registration of continue fourth FDA alisertib cancer to positive half before with quarter of the trial squamous for an milestones X/X RB-deficient, anticipate breast and of the second XXXX development cell for This alisertib HERX ongoing of program a the receptor the X lung hormone Phase potentially that neck in discuss clinical several the with conducting in pembrolizumab the the and year. pathway treatment of trial from in clinical cancer includes coming in the clinical will negative cancer and the patients year, investigator-sponsored data plus this Phase head of in initiating reporting the cell small meeting to end alisertib in alisertib be
will As drugs keep and prior commercial to as R&D, investors company progresses. on evaluate investor regulatory mentioned potentially this allow and to it infrastructure. calls, on updated response continues the its that earnings continue several to itself would in-license leverage existing company to Puma questions, to The diversify in
Jeff Chief quarter. I of will call the to for over the a Ludwig, our commercial now Commercial Officer, performance turn during review Puma's
